Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.23
EGLT's Cash to Debt is ranked lower than
77% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. EGLT: 1.23 )
Ranked among companies with meaningful Cash to Debt only.
EGLT' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: N/A Max: No Debt
Current: 1.23
Equity to Asset 0.19
EGLT's Equity to Asset is ranked lower than
88% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
EGLT' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.5 Max: 0.85
Current: 0.19
0.19
0.85
F-Score: 3
Z-Score: -2.05
M-Score: 2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -227.83
EGLT's Operating margin (%) is ranked lower than
61% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. EGLT: -227.83 )
Ranked among companies with meaningful Operating margin (%) only.
EGLT' s Operating margin (%) Range Over the Past 10 Years
Min: -1934.17  Med: -692.37 Max: -227.83
Current: -227.83
-1934.17
-227.83
Net-margin (%) -251.51
EGLT's Net-margin (%) is ranked lower than
63% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. EGLT: -251.51 )
Ranked among companies with meaningful Net-margin (%) only.
EGLT' s Net-margin (%) Range Over the Past 10 Years
Min: -2250.73  Med: -740.47 Max: -251.51
Current: -251.51
-2250.73
-251.51
ROE (%) -113.60
EGLT's ROE (%) is ranked lower than
83% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. EGLT: -113.60 )
Ranked among companies with meaningful ROE (%) only.
EGLT' s ROE (%) Range Over the Past 10 Years
Min: -444.79  Med: -265.8 Max: -86.8
Current: -113.6
-444.79
-86.8
ROA (%) -48.16
EGLT's ROA (%) is ranked lower than
66% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. EGLT: -48.16 )
Ranked among companies with meaningful ROA (%) only.
EGLT' s ROA (%) Range Over the Past 10 Years
Min: -307.77  Med: -140.37 Max: -48.16
Current: -48.16
-307.77
-48.16
ROC (Joel Greenblatt) (%) -701.75
EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. EGLT: -701.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EGLT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1093.04  Med: -854.74 Max: -672.52
Current: -701.75
-1093.04
-672.52
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
Q3 2015

EGLT Guru Trades in Q3 2015

Jim Simons 31,800 sh (-12.64%)
» More
Q4 2015

EGLT Guru Trades in Q4 2015

Jim Simons 47,300 sh (+48.74%)
» More
Q1 2016

EGLT Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:VTVT, OTCPK:SPHRY, NAS:KMDA, NAS:CYAD, NAS:VTL, NAS:DVAX, NAS:MDGL, NAS:CDTX, OTCPK:NICXF, OTCPK:DGJI, NAS:PRTO, NAS:AGTC, NAS:ALBO, NAS:CBMG, NAS:IMDZ, NAS:VCYT, NAS:CDXS, NAS:ARGS, NAS:IMGN, AMEX:PIP » details
Egalet Corp is a specialty pharmaceutical company. The Company is engaged in developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications.

Ratios

vs
industry
vs
history
P/B 8.76
EGLT's P/B is ranked lower than
76% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. EGLT: 8.76 )
Ranked among companies with meaningful P/B only.
EGLT' s P/B Range Over the Past 10 Years
Min: 1.41  Med: 3.26 Max: 9.79
Current: 8.76
1.41
9.79
P/S 6.19
EGLT's P/S is ranked higher than
69% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. EGLT: 6.19 )
Ranked among companies with meaningful P/S only.
EGLT' s P/S Range Over the Past 10 Years
Min: 3.5  Med: 55.33 Max: 670
Current: 6.19
3.5
670
Current Ratio 4.36
EGLT's Current Ratio is ranked higher than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. EGLT: 4.36 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.6 Max: 29.19
Current: 4.36
0.86
29.19
Quick Ratio 4.30
EGLT's Quick Ratio is ranked higher than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. EGLT: 4.30 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 4.53 Max: 29.19
Current: 4.3
0.86
29.19
Days Inventory 150.95
EGLT's Days Inventory is ranked lower than
58% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. EGLT: 150.95 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s Days Inventory Range Over the Past 10 Years
Min: 102.49  Med: 102.49 Max: 150.95
Current: 150.95
102.49
150.95
Days Sales Outstanding 46.97
EGLT's Days Sales Outstanding is ranked higher than
63% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. EGLT: 46.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72  Med: 81.92 Max: 321.28
Current: 46.97
4.72
321.28
Days Payable 400.93
EGLT's Days Payable is ranked higher than
92% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. EGLT: 400.93 )
Ranked among companies with meaningful Days Payable only.
EGLT' s Days Payable Range Over the Past 10 Years
Min: 400.93  Med: 827.64 Max: 827.64
Current: 400.93
400.93
827.64

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 169.80
EGLT's Price/Net Current Asset Value is ranked lower than
99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. EGLT: 169.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EGLT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.09  Med: 4.13 Max: 173.2
Current: 169.8
2.09
173.2
Price/Tangible Book 12.86
EGLT's Price/Tangible Book is ranked lower than
81% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. EGLT: 12.86 )
Ranked among companies with meaningful Price/Tangible Book only.
EGLT' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.9  Med: 3.51 Max: 14.68
Current: 12.86
1.9
14.68
Price/Median PS Value 0.11
EGLT's Price/Median PS Value is ranked higher than
96% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. EGLT: 0.11 )
Ranked among companies with meaningful Price/Median PS Value only.
EGLT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.97 Max: 9.26
Current: 0.11
0.07
9.26
Earnings Yield (Greenblatt) (%) -33.25
EGLT's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. EGLT: -33.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EGLT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -318.41  Med: 0 Max: 0
Current: -33.25
-318.41
0

More Statistics

Revenue (TTM) (Mil) $30.23
EPS (TTM) $ -2.96
Short Percentage of Float44.84%
52-Week Range $4.34 - 11.81
Shares Outstanding (Mil)25.19

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 15 37 57 88
EPS ($) -3.63 -3.10 -2.40 -1.35
EPS w/o NRI ($) -3.63 -3.10 -2.40 -1.35
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
EGALET CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Dec 08 2016
What Passage Of The 21st Century Cures Act Means For Biotech Stocks Dec 08 2016
Egalet Corporation Appoints Robert Roche to Board of Directors Dec 08 2016
Egalet Corporation Appoints Robert Roche to Board of Directors Dec 08 2016
Egalet Announces Issuance of New Patent for Egalet-002 and Guardian™ Technology Dec 06 2016
Egalet Announces Filing of Supplemental New Drug Application for OXAYDO® to FDA Dec 01 2016
The FDA's Historic Caution On Abuse Deterrent Labeling Nov 25 2016
Egalet Announces OXAYDO® Receives Pharmaceutical Composition Patent Protection Through 2024 Nov 17 2016
EGALET CORP Financials Nov 16 2016
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 14 2016
Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results Nov 14 2016
EGALET CORP Files SEC form 10-Q, Quarterly Report Nov 08 2016
ETF’s with exposure to Egalet Corp. : November 8, 2016 Nov 08 2016
Egalet Corp. :EGLT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 Nov 07 2016
Why Egalet Investors Should Expect FDA Approval On Arymo By Year-End Nov 07 2016
EGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 04 2016
Q3 2016 Egalet Corp Earnings Release - Before Market Open Nov 04 2016
Egalet reports 3Q loss Nov 04 2016
Egalet reports 3Q loss Nov 04 2016
Egalet Reports Third Quarter 2016 Financial Results Nov 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)